Pop Test Oncology LLC, dba Palisades Therapeutics. –
Pop Test Oncology LLC, doing business as Palisades Therapeutics, has been granted a U.S. patent for a new pharmaceutical composition and personalized treatment method targeting addiction and related disorders.
The patented compounds—PT155, PT156, PT157, and PT158—are next-generation analogs of PT150, a Phase 2 clinical-stage drug shown to reduce addiction behaviors and withdrawal symptoms in preclinical studies. Early research has demonstrated promising results for alcohol, nicotine, opioid, and methamphetamine use disorders, as well as co-occurring anxiety.
A key innovation of the patent is a personalized treatment protocol based on a patient’s cortisol levels, enabling tailored use of glucocorticoid receptor (GCR) antagonists. The approach builds on previous research funded by the Department of Defense and National Institute on Alcohol Abuse and Alcoholism (NIAAA).
The patent also covers multiple delivery systems, including capsules, tablets, and smart pill technologies, and allows for combination therapy with existing medications such as antidepressants and anxiolytics.
Palisades Therapeutics is now seeking private-sector partners, including major pharmaceutical firms, to accelerate development and commercialization.
